InVision Medical Technology

San Francisco, California All United States companies → — Founded 2022

Imaging AI Specialist Specialty-Focused AI

Cardiology Critical Care Emergency Medicine Radiology

Cardiology AI

Seed

Claim this company

Products

InVision Precision Cardiac Amyloid

InVision Medical Technology

Cardiology AI

AI-powered software for echocardiography to detect cardiac amyloidosis, a life-threatening and often underdiagnosed disease, aiming for earlier detection and improved patient outcomes.

See all 1 product →

About InVision Medical Technology

InVision Medical Technology is a healthcare AI company that develops software to enhance the precision and accuracy of cardiovascular imaging through automated echocardiogram analysis. Their AI tools are designed to streamline the interpretation of ultrasounds, standardize measurements, and identify diseases that might otherwise go undiagnosed.

The company’s solutions, such as InVision Precision LVEF and Precision Cardiac Amyloid, are FDA-cleared and analyze standard DICOM echo studies from various vendors like GE, Philips, Siemens, Canon, and handheld POCUS. These AI models can be deployed either in a hospital’s data center or InVision’s validated cloud, integrating with existing PACS, CVIS, and EHR systems. InVision’s technology is built upon a decade of peer-reviewed research and has been published in prominent medical journals, with results from their blinded and randomized clinical trials presented at major cardiology conferences.

Focus Areas

Medical Imaging Medical AI Healthcare Analytics Computer Vision Clinical Trials Echocardiogram Analysis Cardiology AI Automated Reporting Clinical Workflow Automation Cardiac Amyloidosis Screening LVEF Measurement AI Diagnostic Tool Clinical Decision Support PACS Integration EHR Integration Healthcare SaaS Medical Image Deidentification

Business Intelligence

Technology

Cloud-native or on-premise deployment, processes standard DICOM, integrates with PACS, CVIS, and EHR systems, utilizes deep learning and AI models.

What Physicians Need to Know

AI Diagnosis of Heart Disease

InVision Medical Technology specializes in using AI to streamline the interpretation of echocardiograms and identify heart diseases that may be missed by human readers. Their models are integrated into clinical workflows for ease of use by clinicians.

Cardiovascular Imaging & Echocardiography

The company focuses on improving the precision and accuracy of echocardiography, the most common cardiac imaging exam. They offer FDA-cleared AI for automated evaluation of left ventricular ejection fraction (LVEF) and detection of cardiac amyloidosis from standard echocardiographic DICOM images.

Heart Failure & Cardiac Amyloidosis

InVision provides AI detection for cardiac amyloidosis, a rare, underdiagnosed, and treatable disease, from routine echocardiography. Their Precision Cardiac Amyloid algorithm integrates information across multiple standard echocardiographic views.

Left Ventricular Ejection Fraction (LVEF)

InVision Precision LVEF offers automated evaluation of LVEF from standard echocardiographic DICOM images. It is the only AI-Echo product to undergo a blinded, randomized prospective clinical trial, demonstrating time savings and improved clinical precision.

Clinical Workflow Management

InVision's AI models are tightly integrated into the clinical workflow, allowing for easy usage by clinicians. The software sits behind the picture archive, reads the study, and writes its answer back into the same study the cardiologist is about to open, often before the scan is finished.

Disease Screening (Opportunistic Detection)

Beyond cardiac conditions, InVision is developing Precision Cirrhosis for opportunistic detection of cirrhosis and steatotic liver disease directly from the subcostal view already captured during routine echocardiography.

Valvular Heart Disease

InVision is developing AI for multi-valve assessment, including mitral, tricuspid, and aortic valve conditions. Their mitral regurgitation detection was published in Circulation (2024), and tricuspid regurgitation detection in JAMA Cardiology (2025).

Physician Tip

InVision Medical Technology offers FDA-cleared AI tools that integrate seamlessly into existing echocardiography workflows, providing automated measurements and detection of critical conditions like cardiac amyloidosis and LVEF. This can lead to streamlined interpretation, standardized measurements, and the surfacing of undiagnosed diseases, ultimately saving physician and sonographer time and improving diagnostic precision. Their commitment to clinical validation, including the first blinded, randomized clinical trial of AI in cardiology for LVEF, provides a strong evidence base for their technology. Furthermore, their solutions are designed to be vendor-neutral, working with existing PACS, CVIS, and EHR systems, and offer both cloud and on-premise deployment options to address data security and infrastructure preferences. The company has also secured CPT codes and Medicare New Technology Add-on Payments, facilitating reimbursement for their AI-assisted diagnoses.

InVision's solutions are designed for vendor-neutral integration, reading standard DICOM images from various manufacturers like GE, Philips, Siemens, Canon, and handheld POCUS devices. They deploy alongside existing PACS, CVIS, and Epic EHR systems, with results flowing into the study, PACS reporting environment, and EHR. Billing capture is also integrated, allowing a checkbox in the structured report template to record AI usage for CPT 0932T. Deployment can be either in your data center or InVision's validated cloud, ensuring PHI never leaves your network in on-premise deployments and customer data stays within the United States for both options.

Products by InVision Medical Technology

1 product in the directory

InVision Precision Cardiac Amyloid

InVision Medical Technology

Cardiology AI

AI-powered software for echocardiography to detect cardiac amyloidosis, a life-threatening and often underdiagnosed disease, aiming for earlier detection and improved patient outcomes.

What the Web Says

InVision Medical Technology develops AI tools for the rapid and accurate diagnosis of heart disease, focusing on streamlining ultrasound interpretation and identifying undiagnosed conditions. Their products, such as InVision Precision LVEF and Precision Cardiac Amyloid, are FDA-cleared and have undergone clinical trials, with research published in scientific journals like Nature and JAMA Cardiology. While product reviews highlight the effectiveness of their AI in improving diagnostic precision and efficiency, employer reviews for related entities like Invision Diagnostics and Invision Health show a mixed sentiment regarding work-life balance, pay, and management.

Overall: Mixed

Strengths

AI tools streamline ultrasound interpretation and identify undiagnosed diseases.
Products are FDA-cleared and clinically validated.
Demonstrated time savings and improved clinical precision in trials.
Offers both cloud and on-premise deployment options for data security.
Strong focus on research and peer-reviewed publications.
Potential for growth within the company (mentioned in some employer reviews).

Limitations

Some employer reviews cite poor management and communication.
Issues with work-life balance and pay/benefits in some related companies.
Lack of training and disorganization mentioned in employer reviews.
Concerns about high turnover rates in some related entities.
Health insurance can be inadequate (mentioned in employer reviews).
Limited customization in some InVision software products.

Based on reviews from: G2, Capterra, Indeed.com, Reddit, InVision Medical Technology Website, Y Combinator, Cloudtango

Last updated: 2026-10-18

Videos

News, demos, and interviews about InVision Medical Technology.

Loading videos...

Videos load interactively. If none appear, search YouTube for InVision Medical Technology →

View all on YouTube

Press & Coverage

InVision Medical Technology

FDA 510(k) clearance for InVision Precision Cardiac Amyloid

InVision received FDA 510(k) clearance for its AI Software as a Medical Device for detection of cardiac amyloidosis from echocardiogram views. The algorithm had previously been granted Breakthrough Device Designation.

2025-05

InVision Medical Technology

FDA 510(k) clearance for InVision Precision LVEF

InVision received FDA 510(k) clearance for automated evaluation of left ventricular ejection fraction (LVEF) from echocardiographic DICOM studies. Precision LVEF is supported by published blinded, randomized prospective trial evidence.

2024-05

InVision Medical Technology

Medicare establishes dedicated reimbursement for InVision's AI detection of cardiac amyloidosis

CMS finalized a New Technology Add-on Payment (NTAP) for InVision Precision Cardiac Amyloid, providing a defined Medicare payment pathway for inpatient and outpatient settings, effective October 1, 2026.

2026-08

InVision Medical Technology

Partnership with Dandelion Health gives life sciences a new class of cardiac data

InVision's echocardiography AI is now live on Dandelion Health's Clinical AI Marketplace, enabling the generation of significantly more cardiac measurements from raw imaging data.

2026-04

EIN Presswire

IMVARIA Labs Adopts InVision Precision Cardiac Amyloid

IMVARIA's AI Lab will offer InVision Precision Cardiac Amyloid, making the FDA-cleared AI for cardiac amyloidosis detection available on a referral basis to clinicians.

2026-10

InVision Medical Technology

FDA Breakthrough Device Designation for Precision Cirrhosis

The FDA granted Breakthrough Device status to Precision Cirrhosis, InVision's AI for opportunistic detection of end-stage liver disease from routine echocardiography.

2025-11

InVision Medical Technology

AMA adopts CPT billing code for Precision Cardiac Amyloid

The American Medical Association adopted a new Category III CPT code (0932T) covering AI adjunctive technologies for evaluating patients with heart failure symptoms, effective January 1, 2025.

2024-07

Nature

Blinded, randomized trial of sonographer versus AI cardiac function assessment

This peer-reviewed article details the first-ever blinded, randomized clinical trial of AI in cardiology, demonstrating the efficacy of InVision's technology in reducing sonographer and cardiologist effort while improving measurement consistency for LVEF.

2023-04

Frequently Asked Questions

How does InVision Medical Technology's AI platform specifically aid in the diagnosis of heart disease, particularly in complex conditions like cardiac amyloidosis?

InVision Medical Technology's AI platform leverages advanced algorithms to analyze cardiovascular imaging, including echocardiography, to detect subtle patterns indicative of various heart diseases. For complex conditions like cardiac amyloidosis, the AI assists in identifying specific morphological and functional changes that might be missed by the human eye, improving diagnostic accuracy and timeliness.

What InVision products are available to enhance the efficiency of cardiovascular imaging and echocardiography workflows, and how do they integrate with existing clinical systems?

InVision offers a suite of products designed to streamline cardiovascular imaging and echocardiography workflows, from automated measurements of parameters like Left Ventricular Ejection Fraction (LVEF) to comprehensive reporting tools. Our solutions are built with interoperability in mind, utilizing industry-standard protocols to seamlessly integrate with most Electronic Health Record (EHR) and Picture Archiving and Communication System (PACS) systems, minimizing disruption to existing clinical workflows.

What are InVision Medical Technology's compliance standards and regulatory clearances for its AI diagnostic tools in cardiovascular care?

InVision Medical Technology adheres to stringent compliance standards and has obtained necessary regulatory clearances for its AI diagnostic tools in cardiovascular care. Our products are developed in accordance with medical device regulations, ensuring data privacy, security, and clinical efficacy.

How does InVision Medical Technology address concerns regarding false positives or negatives in AI-driven disease screening for heart failure and other cardiovascular conditions?

InVision Medical Technology employs robust validation processes and continuous learning algorithms to minimize false positives and negatives in AI-driven disease screening for heart failure and other cardiovascular conditions. Our AI models are trained on extensive, diverse datasets and are designed to provide clinicians with actionable insights while clearly indicating confidence levels, empowering physicians to make the final diagnostic decisions.

Can you provide information on the pricing structure for InVision Medical Technology's AI solutions and the level of technical support and training provided to healthcare facilities?

InVision Medical Technology offers flexible pricing structures tailored to the needs of individual healthcare facilities, ranging from subscription models to per-study fees. We provide comprehensive technical support, including dedicated account managers, 24/7 helpdesk access, and ongoing training programs to ensure seamless integration and optimal utilization of our AI solutions by clinical staff.

What is InVision Medical Technology's strategy for partnerships with other healthcare technology companies or research institutions, and what is the company's long-term stability outlook?

InVision Medical Technology actively pursues strategic partnerships with leading healthcare technology companies and research institutions to further innovate and expand the capabilities of our AI platform. Our long-term stability is underpinned by a strong investment in research and development, a growing customer base, and a commitment to addressing critical unmet needs in cardiovascular diagnostics.

Comparisons

InVision Precision Cardiac Amyloid vs EchoNext

InVision Precision Cardiac Amyloid vs MAGNETOM Cima.X

InVision Precision Cardiac Amyloid vs V7 Diagnostic Ultrasound System

InVision Precision Cardiac Amyloid vs uPMR 790

Related Companies

Suggest an Edit → | Report an issue